A pharmaceutical company is preparing a post-approval variat…
A pharmaceutical company is preparing a post-approval variation for a medicine registered in South Africa. They notice the European Union (EU) Variations Guideline classifies changes into Type IA, IB, and II, while SAHPRA has published a Variations Addendum for local submissions. Which statement best describes the relationship between the EU Variations Guideline and the SAHPRA Variations Addendum?